Immune checkpoint inhibition in advanced esophageal squamous cell carcinoma: how can we personalise management?

Cagney, Hannah; Petty, Russell; Baxter, Mark

doi:10.21037/jtd-23-598

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with advanced ESCA who are not eligible for radical treatment could choose to receive chemotherapy or immune checkpoint inhibitor (ICI) therapy. Importantly, it has been demonstrated that ICI is more effective and safer than chemotherapy for patients with advanced ESCA ( 4 , 5 ). ESCA is a highly heterogeneous disease with a widely varying prognosis among patients, with no available prognostic markers and limited clinically targeted therapies ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

Identification of enhancer RNA AC005515.1 as a novel biomarker for prognosis in esophageal cancer and predictors of immunotherapy response

Jia,

Chen,

Zhao

et al. 2023

Transl Cancer Res

View full text Add to dashboard Cite

Background The enhancer RNA (eRNA) signature shows excellent promise in the prognostic role of many malignancies, but its value has not been fully explored in esophageal cancer (ESCA). Methods We comprehensively analyzed 33 oncogene expression matrices and clinical data from The Cancer Genome Atlas (TCGA) and identified ESCA prognostic-related key eRNAs by Kaplan-Meier and co-expression analysis. We also investigated the prognostic role of the key eRNA using a series of bioinformatics approaches, including immune infiltration, immune function, immune subtypes, and the tumor microenvironment. Finally, the tumor immune dysfunction and exclusion (TIDE) score was used to predict the immune response to immune checkpoint blockade (ICB) therapy. Results We identified eRNA AC005515.1, AC012368.1, AP003469.2, Clorf61, and WDFY3-AS2 were associated with the prognosis of ESCA. AC005515.1 is a critical prognostic-related eRNA in ESCA and was significantly co-expressed with immune checkpoint genes ( CTLA4 , CD274 , etc.). In the pan-cancer analysis, AC005515.1 was also associated with the prognosis of seven cancers, including kidney renal papillary cell carcinoma and low-grade brain glioma. It was also found to be co-expressed with immune checkpoint genes in these tumors. Moreover, high expression of AC005515.1 was associated with CD8 + T cells and M1 macrophages infiltration, and the AC005515.1 high-expression group had a higher TIDE score in ESCA. Conclusions Overall, eRNA AC005515.1 is associated with the local immune environment of ESCA and may become a new biomarker of ESCA prognosis and immunotherapy response.

show abstract